Over the weekend, Health Secretary Robert F. Kennedy Jr. almost advanced a dramatic change to the U.S. childhood immunization schedule by signaling support for Denmark’s smaller routine program. Politico reported that Kennedy canceled a Friday-afternoon press briefing where he would have advised parents to consider Denmark’s schedule as an option. The cancellation came after internal legal and political concerns emerged, and public-health experts quickly criticized the rationale and warned about risks from comparing two very different health systems. Despite the setback, officials and observers expect this issue to resurface.
Key Takeaways
- Politico reported that a press conference scheduled for Friday was canceled after RFK Jr. planned to recommend Denmark’s vaccine schedule for U.S. parents.
- Denmark universally recommends vaccines for 10 diseases; the United States currently recommends universal vaccination for 16 diseases (it was 17 before ACIP’s recent change removing a hepatitis B universal recommendation).
- At an early-December ACIP meeting, Tracy Beth Høeg, acting director of FDA’s CDER, presented Denmark’s schedule and argued it merited consideration.
- President Donald Trump issued an executive order on December 5 directing review of alignment with peer countries, setting the political backdrop for the proposal.
- Anonymous HHS officials told Politico the Office of the General Counsel warned the change could invite a successful lawsuit and that the move would be “politically risky.”
- An HHS spokesperson told Gizmodo that any suggested reasons beyond HHS statements are “pure speculation.”
- Public-health experts and Danish officials said the Danish schedule is not directly transferable given differences in health systems, screening, and vaccination history.
Background
The debate began to escalate in early December when ACIP members and FDA staff reviewed foreign immunization models. Tracy Beth Høeg presented Denmark’s routine program at a Committee meeting, highlighting a smaller set of universal recommendations. Shortly afterwards, President Trump issued an executive order on December 5 urging federal agencies to consider aligning parts of U.S. health policy with other high-income countries, which put additional pressure on HHS to produce a visible policy response.
Denmark’s system rests on a universal, integrated health-care infrastructure and long-standing screening programs, which public-health scholars say make its immunization choices feasible there but not automatically exportable. The U.S. system is fragmented, with state-level variation, private and public payers, and a different epidemiologic history for some vaccine-preventable diseases. The U.S. formerly limited hepatitis B vaccination to high-risk groups before moving to universal newborn immunization; that earlier policy change is cited as a precedent for how targeted approaches can fail to control transmission.
Main Event
HHS announced a press briefing for Friday where Health Secretary RFK Jr. was expected to endorse Denmark’s schedule as an alternative parents could follow. According to Politico, the briefing was canceled hours before it was to occur. Anonymous senior HHS officials told Politico the Office of the General Counsel judged the abrupt policy shift legally vulnerable and likely to prompt successful litigation; another official called it politically hazardous.
Gizmodo reported that RFK Jr. and his supporters had been signaling this shift for weeks, and that the cancellation reflected last-minute second thoughts rather than a change in intent. Officials within HHS declined to expand beyond the public statement that reasons not stated by HHS are “pure speculation,” while unnamed sources described internal concern about legal exposure and backlash from public-health communities.
Experts outside the agency uniformly criticized the plan to import Denmark’s recommendations without accounting for structural differences between the countries. Statens Serum Institut researchers and other academics said Denmark’s fewer recommendations depend on robust screening, lower baseline disease prevalence for certain infections, and universal access to primary care—conditions not uniformly present across the U.S.
Analysis & Implications
Adopting a foreign vaccine schedule without comprehensive, evidence-based review could erode public confidence in immunization programs. Vaccine schedules are built on country-specific disease burden, population immunity, health-system capacity, and surveillance capabilities; transplanting a schedule risks leaving gaps in protection if the supporting systems are not equivalent. In the case of hepatitis B, U.S. experience shows that targeted strategies failed to substantially reduce incidence until universal newborn vaccination was implemented.
The legal concerns flagged by HHS counsel underscore another constraint: administrative agencies must base programmatic changes on transparent rule-making and solid scientific justification to survive judicial review. A sudden public recommendation from the Secretary that effectively narrows federal guidance could be challenged as arbitrary or procedurally deficient, particularly where public-health bodies such as ACIP and CDC historically guide immunization policy.
Politically, the episode aligns with a broader anti- or vaccine-skeptical strand in some quarters of U.S. politics; relying on that momentum risks conflating political objectives with medical guidance. If the administration pursues similar shifts again, the likely consequence is prolonged litigation, state-level heterogeneity in policy adoption, and messaging confusion that could depress vaccination coverage.
Comparison & Data
| Country | Universal recommended vaccines (count) | Notes |
|---|---|---|
| Denmark | 10 | Universal system; strong screening and integrated primary care |
| United States | 16 | Fragmented health system; 17 until ACIP removed a hepatitis B universal recommendation |
The raw counts (10 vs. 16) simplify deeper differences: which vaccines are included, timing, catch-up policies, and population immunity levels all matter for outcomes. Several other high-income countries—Canada, Germany, Japan—recommend numbers closer to the U.S., and some, like the U.K., are adding vaccines (the U.K. plans to introduce routine varicella vaccination next year). These dynamics indicate a general trend toward maintaining or expanding routine protection in many peer countries, not systematic downsizing.
Reactions & Quotes
Public and institutional responses were swift. Danish public-health researchers characterized the use of Denmark as a template without considering system differences as baffling. HHS officials emphasized procedural caution when discussing the cancelled briefing.
“It’s not at all fair to say look at Denmark unless you can match the other characteristics of Denmark.”
Anders Hviid, Statens Serum Institut (as reported to The New York Times)
Context: Hviid, who leads vaccine-safety and effectiveness research at Denmark’s public-health institute, told reporters that a direct policy transfer does not account for structural and epidemiologic differences between Denmark and the United States.
“Any reasons for the press conference’s cancellation not provided by HHS are pure speculation.”
HHS spokesperson (statement to Gizmodo)
Context: The spokesperson repeated HHS’s public-line response and declined to elaborate on internal counsel advice or political deliberations.
Unconfirmed
- Whether RFK Jr. would have formally issued a directive—rather than an advisory recommendation—had the briefing proceeded; documentation of intent has not been released.
- The precise legal memo content from the HHS Office of the General Counsel and whether it was definitive or advisory has not been publicly disclosed.
- The extent to which internal political lobbying influenced the cancellation beyond the counsel’s legal assessment remains unverified.
Bottom Line
This episode illustrates the fragility of vaccine-policy deliberation when political pressure intersects with technical public-health decision-making. Country-to-country differences in health-care delivery, disease history, and surveillance make simple numerical comparisons of recommended vaccines misleading and risky as a basis for policy change.
Any durable revision to the U.S. routine schedule should proceed through established scientific channels—ACIP review, CDC assessment, public comment and transparent rule-making—and be supported by data showing safety, effectiveness, and system readiness. Expect further attempts to reconfigure guidance; the key question is whether future initiatives will follow rigorous evidence review or remain politically driven.
Sources
- Gizmodo — (news reporting; original story summarizing HHS events)
- Politico — (news reporting; cited for the briefing cancellation)
- The New York Times — (news reporting; quoted Danish researcher)
- Centers for Disease Control and Prevention (CDC) — (official public-health guidance)
- Statens Serum Institut — (official Danish public-health agency)